Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: A population-based study

Virology Journal

Volumn 7, Issue , 2010, Pages

  Ye, Jing ^a   Cheng, Xiaodong ^a   Chen, Xiaojing ^a   Ye, Feng ^a   Lü, Weiguo ^a   Xie, Xing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHINA; CLIMACTERIUM; FEMALE; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POPULATION BASED CASE CONTROL STUDY; PREDICTOR VARIABLE; PREVALENCE; QUESTIONNAIRE; UTERINE CERVICITIS; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; CLASSIFICATION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; RISK FACTOR; SEXUAL BEHAVIOR; UTERINE CERVIX; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

ADULT; AGED; CERVIX UTERI; CHINA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; SEXUAL BEHAVIOR; YOUNG ADULT;

EID: 77951539781     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-66     Document Type: Article

References (39)

1. Chapter 1: HPV in the etiology of human cancer. N Munoz X Castellsague AB de Gonzalez L Gissmann, Vaccine 2006 24 Suppl 3 1 10 10.1016/j.vaccine.2006.05. 115 16122853 (Pubitemid 44293019)
2. Epidemiology of mucosal human papillomavirus infection and associated diseases. H Trottier AN Burchell, Public Health Genomics 2009 12 291 307 10.1159/000214920 19684442
3. A review of human carcinogens - Part B: biological agents. V Bouvard R Baan K Straif Y Grosse B Secretan F El Ghissassi L Benbrahim-Tallaa N Guha C Freeman L Galichet V Cogliano, Lancet Oncol 2009 10 321 322 10.1016/S1470- 2045(09)70096-8 19350698
4. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. J Paavonen D Jenkins FX Bosch P Naud J Salmeron CM Wheeler SN Chow DL Apter HC Kitchener X Castellsague NS de Carvalho SR Skinner DM Harper JA Hedrick U Jaisamrarn GA Limson M Dionne W Quint B Spiessens P Peeters F Struyf SL Wieting MO Lehtinen G Dubin, Lancet 2007 369 2161 2170 10.1016/S0140-6736(07) 60946-5 17602732 (Pubitemid 46977438)
5. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. SM Garland M Hernandez-Avila CM Wheeler G Perez DM Harper S Leodolter GW Tang DG Ferris M Steben J Bryan FJ Taddeo R Railkar MT Esser HL Sings M Nelson J Boslego C Sattler E Barr LA Koutsky, N Engl J Med 2007 356 1928 1943 10.1056/NEJMoa061760 17494926 (Pubitemid 46740303)
6. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. SK Kjaer K Sigurdsson OE Iversen M Hernandez-Avila CM Wheeler G Perez DR Brown LA Koutsky EH Tay P Garcia KA Ault SM Garland S Leodolter SE Olsson GW Tang DG Ferris J Paavonen M Lehtinen M Steben FX Bosch J Dillner EA Joura S Majewski N Munoz ER Myers LL Villa FJ Taddeo C Roberts A Tadesse J Bryan R Maansson S Lu S Vuocolo TM Hesley A Saah E Barr RM Haupt, Cancer Prev Res (Phila Pa) 2009 2 868 878 19789295
7. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. N Munoz R Manalastas Jr P Pitisuttithum D Tresukosol J Monsonego K Ault C Clavel J Luna E Myers S Hood O Bautista J Bryan FJ Taddeo MT Esser S Vuocolo RM Haupt E Barr A Saah, Lancet 2009 373 1949 1957 10.1016/S0140-6736(09)60691-7 19493565
8. Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. SJ Goldie M O'Shea NG Campos M Diaz S Sweet SY Kim, Vaccine 2008 26 4080 4093 10.1016/j.vaccine.2008.04.053 18550229
9. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. R Herrero, J Infect Dis 2009 199 919 922 10.1086/597308 19236278
10. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. GM Clifford S Gallus R Herrero N Munoz PJ Snijders S Vaccarella PT Anh C Ferreccio NT Hieu E Matos M Molano R Rajkumar G Ronco S de Sanjose HR Shin S Sukvirach JO Thomas S Tunsakul CJ Meijer S Franceschi, Lancet 2005 366 991 998 10.1016/S0140-6736(05)67069-9 16168781 (Pubitemid 41323035)
11. Diagnosis of sickle cell anemia and beta-thalassemia with enzymatically amplified DNA and nonradioactive allele-specific oligonucleotide probes. RK Saiki CA Chang CH Levenson TC Warren CD Boehm HH Kazazian Jr HA Erlich, N Engl J Med 1988 319 537 541 3405266
12. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. MM Manos Y Ting DK Wright AJ Lewis TR Broker SM Wolinsky, Cancer Cells 1989 7 209 214
13. Distribution of human papillomavirus genotypes in the patients with cervical carcinoma and its precursors in Zhejiang Province, China. D Hong F Ye H Chen W Lu Q Cheng Y Hu X Xie, Int J Gynecol Cancer 2008 18 104 109 10.1111/j.1525-1438.2007.00968.x 17466048
14. Classification of papillomaviruses. EM de Villiers C Fauquet TR Broker HU Bernard H zur Hausen, Virology 2004 324 17 27 10.1016/j.virol.2004.03.033 15183049 (Pubitemid 38737395)
15. Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. D Grisaru B Avidor J Niv S Marmor B Almog C Leibowitz M Graidy M Giladi, J Clin Microbiol 2008 46 1602 1605 10.1128/JCM.02483-07 18322063 (Pubitemid 351657201)
16. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay by comparison with Roche Linear Array HPV genotyping assay. SS Liu RC Leung KK Chan AN Cheung HY Ngan, J Clin Microbiol 2009 20042614
17. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. M Dai YP Bao N Li GM Clifford S Vaccarella PJ Snijders RD Huang LX Sun CJ Meijer YL Qiao S Franceschi, Br J Cancer 2006 95 96 101 10.1038/sj.bjc.6603208 16773069 (Pubitemid 43980561)
18. Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. LK Li M Dai GM Clifford WQ Yao A Arslan N Li JF Shi PJ Snijders CJ Meijer YL Qiao S Franceschi, Br J Cancer 2006 95 1593 1597 10.1038/sj.bjc.6603450 17088908 (Pubitemid 44863366)
19. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. RF Wu M Dai YL Qiao GM Clifford ZH Liu A Arslan N Li JF Shi PJ Snijders CJ Meijer S Franceschi, Int J Cancer 2007 121 1306 1311 10.1002/ijc.22726 17417776 (Pubitemid 47293798)
20. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. VM Coupe J Berkhof NW Bulkmans PJ Snijders CJ Meijer, Br J Cancer 2008 98 646 651 10.1038/sj.bjc. 6604162 18182990 (Pubitemid 351214513)
21. Epidemiologic risk profile of infection with different groups of human papillomaviruses. PK Chan WC Ho MC Wong AR Chang JS Chor MY Yu, J Med Virol 2009 81 1635 1644 10.1002/jmv.21575 19623668
22. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. S de Sanjose M Diaz X Castellsague G Clifford L Bruni N Munoz FX Bosch, Lancet Infect Dis 2007 7 453 459 10.1016/S1473-3099(07)70158-5 17597569 (Pubitemid 46962343)
23. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. HJ An NH Cho SY Lee IH Kim C Lee SJ Kim MS Mun SH Kim JK Jeong, Cancer 2003 97 1672 1680 10.1002/cncr.11235 12655524 (Pubitemid 36355926)
24. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. H Lin YY Ma JS Moh YC Ou SY Shen CC ChangChien, Gynecol Oncol 2006 101 40 45 10.1016/j.ygyno.2005. 09.028 16256180 (Pubitemid 43303557)
25. Host and viral genetics and risk of cervical cancer: a review. A Hildesheim SS Wang, Virus Res 2002 89 229 240 10.1016/S0168-1702(02)00191-0 12445662 (Pubitemid 35351541)
26. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. M Lin LY Yang LJ Li JR Wu YP Peng ZY Luo, Aust N Z J Obstet Gynaecol 2008 48 189 194 10.1111/j.1479-828X.2008.00844.x 18366494 (Pubitemid 351441617)
27. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. S Sukvirach JS Smith S Tunsakul N Munoz V Kesararat O Opasatian S Chichareon V Kaenploy R Ashley CJ Meijer PJ Snijders P Coursaget S Franceschi R Herrero, J Infect Dis 2003 187 1246 1256 10.1086/373901 12696004 (Pubitemid 36438965)
28. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. JS Smith L Lindsay B Hoots J Keys S Franceschi R Winer GM Clifford, Int J Cancer 2007 121 621 632 10.1002/ijc.22527 17405118 (Pubitemid 46986496)
29. Human papillomavirus type distribution in women from Asia: a meta-analysis. YP Bao N Li JS Smith YL Qiao, Int J Gynecol Cancer 2008 18 71 79 10.1111/j.1525-1438.2007.00959.x 17466054 (Pubitemid 351738815)
30. Risk of female human papillomavirus acquisition associated with first male sex partner. RL Winer Q Feng JP Hughes S O'Reilly NB Kiviat LA Koutsky, J Infect Dis 2008 197 279 282 10.1086/524875 18179386 (Pubitemid 351263448)
31. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. KN Althoff P Paul AE Burke R Viscidi M Sangaramoorthy PE Gravitt, J Womens Health (Larchmt) 2009 18 1341 1346 10.1089/jwh.2008.1223 19702476
32. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. DR Brown ML Shew B Qadadri N Neptune M Vargas W Tu BE Juliar TE Breen JD Fortenberry, J Infect Dis 2005 191 182 192 10.1086/426867 15609227 (Pubitemid 40096375)
33. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. MT Goodman YB Shvetsov K McDuffie LR Wilkens X Zhu PJ Thompson L Ning J Killeen L Kamemoto BY Hernandez, Cancer Res 2008 68 8813 8824 10.1158/0008-5472.CAN-08-1380 18974124
34. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. PE Castle M Schiffman R Herrero A Hildesheim AC Rodriguez MC Bratti ME Sherman S Wacholder R Tarone RD Burk, J Infect Dis 2005 191 1808 1816 10.1086/428779 15871112 (Pubitemid 40705386)
35. Age-related changes of the cervix influence human papillomavirus type distribution. PE Castle J Jeronimo M Schiffman R Herrero AC Rodriguez MC Bratti A Hildesheim S Wacholder LR Long L Neve R Pfeiffer RD Burk, Cancer Res 2006 66 1218 1224 10.1158/0008-5472.CAN-05-3066 16424061 (Pubitemid 43165993)
36. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. FX Bosch X Castellsague N Munoz S de Sanjose AM Ghaffari LC Gonzalez M Gili I Izarzugaza P Viladiu C Navarro A Vergara N Ascunce E Guerrero KV Shah, J Natl Cancer Inst 1996 88 1060 1067 10.1093/jnci/88.15. 1060 8683637 (Pubitemid 26260492)
37. Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. N Munoz X Castellsague FX Bosch L Tafur S de Sanjose N Aristizabal AM Ghaffari KV Shah, J Natl Cancer Inst 1996 88 1068 1075 10.1093/jnci/88.15.1068 8683638 (Pubitemid 26260493)
38. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). SK Kjaer B Chackerian AJ van den Brule EI Svare G Paull JM Walbomers JT Schiller JE Bock ME Sherman DR Lowy CL Meijer, Cancer Epidemiol Biomarkers Prev 2001 10 101 106 11219765 (Pubitemid 32172427)
39. The epidemiology of human papillomavirus infection and cervical cancer. FX Bosch S de Sanjose, Dis Markers 2007 23 213 227 17627057 (Pubitemid 47015785)